Rho kinase inhibition in diabetic nephropathy

Current Opinion in Nephrology and Hypertension

Volumn 20, Issue 1, 2011, Pages 77-83

  Komers, Radko ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Diabetic nephropathy; Fasudil; Rho associated kinase

Indexed keywords

CYTOKINE; GUANOSINE TRIPHOSPHATASE; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; RHO KINASE INHIBITOR;

ADRENAL DISEASE; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL ASSESSMENT; DIABETIC NEPHROPATHY; EXTRACELLULAR MATRIX; FIBROSING ALVEOLITIS; GLOMERULOSCLEROSIS; HEMODYNAMICS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INDIVIDUALIZATION; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; ANIMALS; DIABETIC NEPHROPATHIES; HUMANS; KIDNEY; PROTEIN KINASE INHIBITORS; RHO-ASSOCIATED KINASES; SIGNAL TRANSDUCTION;

EID: 79851508434     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNH.0b013e32834131f8     Document Type: Article

References (39)

1. Shimokawa H, Takeshita A. Rho-kinase is an important therapeutic target in cardiovascular medicine. Arterioscler Thromb Vasc Biol 2005; 25:1767-1775. (Pubitemid 41243442)
2. Loirand G, Guerin P, Pacaud P. Rho kinases in cardiovascular physiology and pathophysiology. Circ Res 2006; 98:322-334.
3. Liao JK, Seto M, Noma K. Rho kinase (ROCK) inhibitors. J Cardiovasc Pharmacol 2007; 50:17-24. (Pubitemid 47220442)
4. Zhang Y, Peng F, Gao B, et al. Mechanical strain-induced RhoA activation requires NADPH oxidase-mediated ROS generation in caveolae. Antioxid Redox Signal 2010; 13:959-973.
5. Peng F, Wu D, Ingram AJ, et al. RhoA activation in mesangial cells by mechanical strain depends on caveolae and caveolin-1 interaction. J Am Soc Nephrol 2007; 18:189-198. (Pubitemid 46053432)
6. Bustelo XR, Sauzeau V, Berenjeno IM. GTP-binding proteins of the Rho/Rac family: regulation, effectors and functions in vivo. Bioessays 2007; 29:356-370. (Pubitemid 46597867)
7. Noma K, Oyama N, Liao JK. Physiological role of ROCKs in the cardiovascular system. Am J Physiol Cell Physiol 2006; 290:C661-C668.
8. Laufs U, Marra D, Node K, Liao JK. 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing Rho GTPase-induced down-regulation of p27(Kip1). J Biol Chem 1999; 274:21926-21931.
9. Rikitake Y, Liao JK. Rho GTPases, statins, and nitric oxide. Circ Res 2005; 97:1232-1235.
10. 2+ sensitivity of smooth muscle and nonmuscle myosin II: modulated by G proteins, kinases, and myosin phosphatase. Physiol Rev 2003; 83:1325-1358. (Pubitemid 37222274)
11. Gorovoy M, Neamu R, Niu J, et al. RhoGDI-1 modulation of the activity of monomeric Rho GTPase RhoA regulates endothelial barrier function in mouse lungs. Circ Res 2007; 101:50-58. (Pubitemid 47094623)
12. Van Nieuw Amerongen GP, Koolwijk P, Versteilen A, van Hinsbergh VW. Involvement of RhoA/Rho kinase signaling in VEGF-induced endothelial cell migration and angiogenesis in vitro. Arterioscler Thromb Vasc Biol 2003; 23:211-217. (Pubitemid 36231930)
13. Ming XF, Viswambharan H, Barandier C, et al. Rho GTPase/Rho kinase negatively regulates endothelial nitric oxide synthase phosphorylation through the inhibition of protein kinase B/Akt in human endothelial cells. Mol Cell Biol 2002; 22:8467-8477. (Pubitemid 35397163)
14. Kanda T, Wakino S, Hayashi K, et al. Effect of fasudil on Rho-kinase and nephropathy in subtotally nephrectomized spontaneously hypertensive rats. Kidney Int 2003; 64:2009-2019. (Pubitemid 37449535)
15. Sun GP, Kohno M, Guo P, et al. Involvements of Rho-kinase and TGF-beta pathways in aldosterone-induced renal injury. J Am Soc Nephrol 2006; 17:2193-2201. (Pubitemid 44141909)
16. Kawamura H, Yokote K, Asaumi S, et al. High glucose-induced upregulation of osteopontin is mediated via Rho/Rho kinase pathway in cultured rat aortic smooth muscle cells. Arterioscler Thromb Vasc Biol 2004; 24: 276-281. (Pubitemid 38197578)
17. Danesh FR, Sadeghi MM, Amro N, et al. 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTPase/p21 signaling pathway: implications for diabetic nephropathy. Proc Natl Acad Sci U S A 2002; 99:8301-8305. (Pubitemid 34651047)
18. Kolavennu V, Zeng L, Peng H, et al. Targeting of RhoA/ROCK signaling ameliorates progression of diabetic nephropathy independent of glucose control. Diabetes 2008; 57:714-723.
19. Peng F, Wu D, Gao B, et al. RhoA/Rho-kinase contribute to the pathogenesis of diabetic renal disease. Diabetes 2008; 57:1683-1692.
20. Hirose A, Tanikawa T, Mori H, et al. Advanced glycation end products increase endothelial permeability through the RAGE/Rho signaling pathway. FEBS Lett 2010; 584:61-66.
21. Reiniger N, Lau K, McCalla D, et al. Deletion of the receptor for advanced glycation end products reduces glomerulosclerosis and preserves renal function in the diabetic OVE26 mouse. Diabetes 2010; 59:2043-2054.
22. Galle J, Mameghani A, Bolz SS, et al. Oxidized LDL and its compound lysophosphatidylcholine potentiate AngII-induced vasoconstriction by stimulation of RhoA. J Am Soc Nephrol 2003; 14:1471-1479. (Pubitemid 36687048)
23. Seibold S, Schurle D, Heinloth A, et al. Oxidized LDL induces proliferation and hypertrophyin human umbilical vein endothelial cells via regulation of p27Kip1 expression: role of RhoA. J Am Soc Nephrol 2004; 15:3026-3034. (Pubitemid 39578834)
24. Banes-Berceli AK, Shaw S, Ma G, et al. Effect of simvastatin on high glucose- and angiotensin II-induced activation of the JAK/STAT pathway in mesangial cells. Am J Physiol Renal Physiol 2006; 291:F116-F121. (Pubitemid 43945941)
25. Zeng L, Xu H, Chew TL, et al. HMG CoA reductase inhibition modulates VEGF-induced endothelial cell hyperpermeability by preventing RhoA activation and myosin regulatory light chain phosphorylation. FASEB J 2005; 19:1845-1847. (Pubitemid 41598770)
26. Xu H, Zeng L, Peng H, et al. HMG-CoA reductase inhibitor simvastatin mitigates VEGF-induced 'inside-out' signaling to extracellular matrix by preventing RhoA activation. Am J Physiol Renal Physiol 2006; 291:F995-F1004. (Pubitemid 44773681)
27. Heusinger-Ribeiro J, Eberlein M, Wahab NA, Goppelt-Struebe M. Expression of connective tissue growth factor in human renal fibroblasts: regulatory roles of RhoA and cAMP. J Am Soc Nephrol 2001; 12:1853-1861. (Pubitemid 32801360)
28. Watts KL, Spiteri MA. Connective tissue growth factor expression and induction by transforming growth factor-beta is abrogated by simvastatin via a Rho signaling mechanism. Am J Physiol Lung Cell Mol Physiol 2004; 287:L1323-L1332. (Pubitemid 39507212)
29. Axelsson J, Rippe A, Rippe B. Acute hyperglycemia induces rapid, reversible increases in glomerular permeability in nondiabetic rats. Am J Physiol Renal Physiol 2010; 298:F1306-F1312.
30. Cavarape A, Bauer J, Bartoli E, et al. Effects of angiotensin II, arginine vasopressin and tromboxane A2 in renal vascular bed: role of Rho-kinase. Nephrol Dial Transplant 2003; 18:1764-1769. (Pubitemid 37098546)
31. Anderson S, Komers R. Pathogenesis of diabetic glomerulopathy: the role of glomerular hemodynamic factors. In: Mogensen CE, editor. The kidney and hypertension in diabetes mellitus. Boston: Kluwer Academic Publishers; 2000. pp. 281-294.
32. Komers R, Oyama TT, Beard DR, Anderson S. Effects of systemic inhibition of Rho kinase on blood pressure and renal hemodynamics in diabetic rats. Br J Pharmacol 2010 [Epub ahead of print].
33. Gojo A, Utsunomiya K, Taniguchi K, et al. The Rho-kinase inhibitor, fasudil, attenuates diabetic nephropathy in streptozotocin-induced diabetic rats. Eur J Pharmacol 2007; 568:242-247. (Pubitemid 46976901)
34. Komers R, Oyama TT, Beard DR, et al. Effect of Rho kinase inhibition on the development of nephropathy in uninephrectomized diabetic rats. Kidney Int [Epub ahead of print].
35. Patel S, Takagi KI, Suzuki J, et al. RhoGTPase activation is a key step in renal epithelial mesenchymal transdifferentiation. J Am Soc Nephrol 2005; 16:1977-1984. (Pubitemid 41716428)
36. Rodrigues-Diez R, Carvajal-Gonzalez G, Sanchez-Lopez E, et al. Pharmacological modulation of epithelial mesenchymal transition caused by angiotensin II. Role of ROCK and MAPK pathways. Pharm Res 2008; 25:2447-2461.
37. Kikuchi Y, Yamada M, Imakiire T, et al. A Rho-kinase inhibitor, fasudil, prevents development of diabetes and nephropathy in insulin-resistant diabetic rats. J Endocrinol 2007; 192:595-603. (Pubitemid 46455962)
38. +/- haploinsufficient mice. Circulation 2005; 112:2959-2965. (Pubitemid 41612298)
39. Vicari RM, Chaitman B, Keefe D, et al. Efficacy and safety of fasudil in patients with stable angina: a double-blind, placebo-controlled, phase 2 trial. J Am Coll Cardiol 2005; 46:1803-1811. (Pubitemid 41579800)